The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myelofibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

Some of the key takeaways from the Myelofibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years. 
• Myelofibrosis companies working in the treatment market are Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, AbbVie, Kartos Therapeutics, Galecto, Lynk Pharmaceuticals, and others, are developing therapies for the Myelofibrosis treatment 

• Emerging Myelofibrosis therapies in the different phases of clinical trials are- Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, Navitoclax, KRT-232, GB-2064, LNK01002, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.   
• In June 2022, “Cellenkos reported FDA clearance of its Investigational New Drug (IND) application, allowing the initiation of a Phase Ib open-label study for CK0804 as an additional therapy to ruxolitinib. This study targets patients with myelofibrosis who have an insufficient response to ruxolitinib.”
• In June 2022, “Imago Biosciences shared recent favorable findings from the ongoing global Phase II clinical trial investigating bomedemstat in individuals with advanced myelofibrosis. The results indicated that bomedemstat demonstrated a favorable safety profile and was well-tolerated among patients with myelofibrosis.”
• In June 2022, “The US FDA has awarded Orphan Drug Designation to TP-3654, Sumitomo Pharma Oncology’s exclusive investigational oral inhibitor targeting PIM kinases. This designation is specifically for treating myelofibrosis.”
• In June 2022, “AbbVie released updated findings from Cohort 3 of the Phase II REFINE trial concerning investigational navitoclax used alongside ruxolitinib in patients new to JAK inhibitors for myelofibrosis (MF), a challenging and uncommon blood cancer. The data underscores the significance of early intervention in myelofibrosis, hinting at the possibility of enhancing clinical results.”
• In February 2022, “Active Biotech has secured an exclusive license deal with Oncode Institute in the Netherlands, obtaining global rights to patents associated with tasquinimod and other S100 inhibitors for treating myelofibrosis.” 

Myelofibrosis Overview

A fibrous substance that resembles scar tissue gradually replaces healthy bone marrow tissue in a rare condition called myelofibrosis.It is included in the category of myeloproliferative illnesses, which are blood disorders, and is categorized as a kind of chronic leukemia.

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:

• Tasquinimod: Active Biotech
• HC-X027: Hinova Pharmaceuticals
• ABBV-744: AbbVie
• IOA-244: iOnctura
• TP-3654: Sumitomo Pharma Oncology
• PXS-5505: Pharmaxis
• KER-050: Keros Therapeutics
• NS-018: Nippon Shinyaku
• Parsaclisib: Incyte Corporation
• Pelabresib: MorphoSys
• Imetelstat: Geron Corporation
• Navitoclax: AbbVie
• KRT-232: Kartos Therapeutics
• GB-2064: Galecto
• LNK01002: Lynk Pharmaceuticals

Myelofibrosis Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Myelofibrosis Molecule Type

Myelofibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Myelofibrosis Pipeline Therapeutics Assessment

• Myelofibrosis Assessment by Product Type
• Myelofibrosis By Stage and Product Type
• Myelofibrosis Assessment by Route of Administration
• Myelofibrosis By Stage and Route of Administration
• Myelofibrosis Assessment by Molecule Type
• Myelofibrosis by Stage and Molecule Type

DelveInsight’s Myelofibrosis Report covers around 45+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies

Some of the key companies in the Myelofibrosis Therapeutics Market include:

Key companies developing therapies for Myelofibrosis are – Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences,  Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others.

Myelofibrosis Pipeline Analysis:

The Myelofibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies

Myelofibrosis Pipeline Market Drivers

• Increase in R&D for the development of new and effective drug for the treatment, increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Pipeline Market Barriers

• However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of Myelofibrosis Pipeline Drug Insight    

• Coverage: Global
• Key Myelofibrosis Companies: Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, AbbVie, Kartos Therapeutics, Galecto, Lynk Pharmaceuticals, and others
• Key Myelofibrosis Therapies: Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, Navitoclax, KRT-232, GB-2064, LNK01002, and others
• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers 

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Myelofibrosis Report Introduction

2. Myelofibrosis Executive Summary

3. Myelofibrosis Overview

4. Myelofibrosis- Analytical Perspective In-depth Commercial Assessment

5. Myelofibrosis Pipeline Therapeutics

6. Myelofibrosis Late Stage Products (Phase II/III)

7. Myelofibrosis Mid Stage Products (Phase II)

8. Myelofibrosis Early Stage Products (Phase I)

9. Myelofibrosis Preclinical Stage Products

10. Myelofibrosis Therapeutics Assessment

11. Myelofibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myelofibrosis Key Companies

14. Myelofibrosis Key Products

15. Myelofibrosis Unmet Needs

16 . Myelofibrosis Market Drivers and Barriers

17. Myelofibrosis Future Perspectives and Conclusion

18. Myelofibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services